Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone

The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with metastatic or unresectable melanoma with BRAF-mutation positive or wild-type (WT) BRAF, respectively.

Study Overview

• Status: Completed
• Conditions: Melanoma
• Intervention / Treatment: Biological: Durvalumab; Drug: Dabrafenib; Drug: Trametinib

Detailed Description

This is a multicenter, open-label study with a dose escalation phase followed by an expansion phase of durvalumab administered in combination with dabrafenib and trametinib or with trametinib alone in participants with BRAF V600 mutation-positive and WT unresectable or metastatic melanoma, respectively.

• Study Type: Interventional
• Enrollment (Actual): 68
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 2M9
      • Research Site
  • Quebec
    • Montreal, Quebec, Canada, H3A 1A1
      • Research Site
• France
  • Villejuif, France, 94805
    • Research Site
• Italy
  • Napoli, Italy, 80131
    • Research Site
• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85258
      • Research Site
  • California
    • Los Angeles, California, United States, 90095
      • Research Site
    • San Francisco, California, United States, 94115
      • Research Site
  • Florida
    • Miami Beach, Florida, United States, 33140
      • Research Site
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Research Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Research Site
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adults >= 18 years old
• Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic) and determined to be BRAF V600E or V600K mutation-positive (cohort A) or mutation-negative (cohorts B and C)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Measurable disease by radiographic or physical examination
• Adequate organ and marrow function
• Willingness to provide consent for biopsies positive or BRAF WT measurable disease and adequate organ and marrow function

Exclusion Criteria:

• Prior treatment with a BRAF inhibitor or MEK inhibitor
• Any prior Grade >= 3 immune-related adverse event while receiving immunotherapy
• Active or prior documented autoimmune disease within the past 2 years
• History of or current risk for retinal vein occlusion (RVO) or central serous retinopathy (CSR)
• History of or current cardiovascular risk including myocardial infarction, >= Class II congestive heart failure, uncontrolled arrhythmias, or refractory hypertension
• Active, untreated central nervous system (CNS) metastases
• Women who are pregnant or lactating

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib; Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.	Biological: Durvalumab; Intravenous dose of 3 or 10 mg/kg durvalumab.; Drug: Dabrafenib; Oral dose of 150 mg dabrafenib capsule.; Drug: Trametinib; Oral dose of 2 mg trametinib tablet.
Experimental: Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib; Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.	Biological: Durvalumab; Intravenous dose of 3 or 10 mg/kg durvalumab.; Drug: Dabrafenib; Oral dose of 150 mg dabrafenib capsule.; Drug: Trametinib; Oral dose of 2 mg trametinib tablet.
Experimental: Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent); Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib.	Biological: Durvalumab; Intravenous dose of 3 or 10 mg/kg durvalumab.; Drug: Trametinib; Oral dose of 2 mg trametinib tablet.
Experimental: Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential); Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.	Biological: Durvalumab; Intravenous dose of 3 or 10 mg/kg durvalumab.; Drug: Trametinib; Oral dose of 2 mg trametinib tablet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Dose Limiting Toxicities (DLTs)	Dose limiting toxicities are defined as any Grade 3 or higher treatment-related (related to any study drug) toxicity that occurs during the DLT evaluation period. Number of participants with DLTs are reported.	From first dose of study drug (Day 1) until the planned 3rd dose of durvalumab (Day 29)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)	An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.	From first dose of study drug (Day 1) up to 90 days after the last dose (up to 4.5 years)
Number of Participants With Abnormal Vital Signs and Physical Examinations Reported as TEAEs	Number of participants with abnormal vital signs and physical examinations reported as TEAEs are reported.	From first dose of study drug (Day 1) up to 90 days after the last dose (up to 4.5 years)
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.	From first dose of study drug (Day 1) up to 90 days after the last dose (up to 4.5 years)
Number of Participants With Abnormal Electrocardiograms (ECGs) and Echocardiograms (ECHOs) Reported as TEAEs	Number of participants with abnormal electrocardiograms (ECGs) and echocardiograms (ECHOs) reported as TEAEs are reported.	From first dose of study drug (Day 1) up to 90 days after the last dose (up to 4.5 years)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Objective Response (OR)	Objective Response is defined as confirmed complete response (CR) or confirmed partial response (PR) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). A confirmed CR is defined as two CRs that were separated by at least 28 days. A confirmed PR is defined as two PRs or an un-confirmed PR and an un-confirmed CR that were separated by at least 28 days. A CR is defined as disappearance of all target and non-target lesions, normalization of tumor marker level and any pathological lymph nodes selected as target lesions must have a reduction in short axis to less than 10 mm. A PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.	From the first dose of study drug until last participant completes 12 months of treatment (assessed up to 4.5 years)
Duration of Response (DOR)	Duration of response: Duration from first documentation of OR to first documented PD or death due to any cause, whichever occurs first. CR: disappearance of all target and non-target lesions, normalization of tumor marker level and any pathological lymph nodes selected as target lesions must have a reduction in short axis to less than 10 mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of >= 5 mm, taking as reference smallest sum of diameters since treatment started including baseline sum of diameters.	From the first dose of study drug until last participant completes 12 months of treatment (assessed up to 4.5 years)
Progression-free Survival (PFS)	Progression-free Survival is defined as duration from the start of treatment with study drug until the first documented PD or death, whichever comes first. PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of >= 5 mm, taking as reference smallest sum of diameters since treatment started including baseline sum of diameters. For participants who are alive and progression-free at the time of data cut-off for analysis, PFS was to be censored at the last tumor assessment date.	From the first dose of study drug until last participant completes 12 months of treatment (assessed up to 4.5 years)
Overall Survival	Overall survival (OS) is measured from the start of treatment until death. For participants who are alive at the end of study or lost to follow-up, OS was censored on the last date when participants are known to be alive.	From the first dose of study drug until last participant completes 12 months of treatment (assessed up to 4.5 years)
Percentage of Participants With Disease Control	Disease control is defined as confirmed CR or PR, or stable disease (SD) that was maintained for >= 12 weeks based on RECIST v1.1. A confirmed CR is defined as two CRs that were separated by at least 28 days. A confirmed PR is defined as two PRs or an un-confirmed PR and an un-confirmed CR that were separated by at least 28 days. CR: disappearance of all target and non-target lesions, normalization of tumor marker level and any pathological lymph nodes selected as target lesions must have a reduction in short axis to less than 10 mm. A PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. A SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of diameters while on study.	From the first dose of study drug until last participant completes 12 months of treatment (assessed up to 4.5 years)
Maximum Observed Plasma Concentration after First Dose (Cmax, 1st) of Durvalumab	Maximum observed plasma concentration of durvalumab after first dose is reported.	Cohorts A and B: End of infusion on Day 1; Cohort C: End of infusion on Day 29
Maximum Observed Plasma Concentration at Steady State (Cmax, ss) of Durvalumab	Maximum observed plasma concentration of durvalumab at steady state is reported.	Cohorts A and B: end of infusion on Day 141; Cohort C: end of infusion on Day 169
Trough Concentration at Steady State (Ctrough) of Durvalumab	Trough concentration of durvalumab pre-dose at steady state is reported.	Cohorts A and B: Pre-dose on Day 141; Cohort C: Pre-dose on Day 169
Number of Participants With Postive Anti-Drug Antibodies (ADA) Titer to Durvalumab	The number of participants with positive serum antibodies to durvalumab post dosing are reported.	Cohorts A and B: Days 1 and 29; Cohort C: Days 29 and 57

Collaborators and Investigators

• Sponsor: MedImmune LLC

Publications and helpful links

General Publications

• Gordon MS, Lutzky J, Lawrence D, Butler M, Ascierto PA, Hug B, et al. Phase 1 study evaluating safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma. Ann Oncol 2014; 25(suppl_4): iv374-iv393 (abstract 8004).
• Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C, Miller W, et al. Phase 1 study combining anti-PD-L1 (MEDI4736) and BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol 2015; 33 (15_suppl): (abstract 3003).
• Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH Jr, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun. 2020 Dec 7;11(1):6262. doi: 10.1038/s41467-020-19810-w. Erratum In: Nat Commun. 2021 Aug 12;12(1):5022.

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2013
• Primary Completion (Actual): April 24, 2018
• Study Completion (Actual): April 24, 2018

Study Registration Dates

• First Submitted: November 20, 2013
• First Submitted That Met QC Criteria: January 2, 2014
• First Posted (Estimate): January 6, 2014

Study Record Updates

• Last Update Posted (Actual): May 17, 2019
• Last Update Submitted That Met QC Criteria: May 15, 2019
• Last Verified: May 1, 2019

More Information

Terms related to this study

• Keywords: Metastatic or Unresectable Melanoma, durvalumab (MEDI4736), dafrafenib, trametinib, BRAF-mutation positive, wild-type BRAF, PD-L1, PD-1
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Melanoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Immunological; Protein Kinase Inhibitors; Durvalumab; Trametinib; Dabrafenib
• Other Study ID Numbers: CD-ON-MEDI4736-1161

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No